The JAK1/JAK2‐ inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release

Abstract

This study demonstrates that the JAK1/JAK2 inhibitor ruxolitinib can inhibit MCactivity, possibly through prevention of STAT5 activation. This renders the JAK-STAT pathway as an interesting target for therapy to release symptom burden in mastocytosis and many other MC mediator-related diseases.